LIR Life Sciences and Neuland Laboratories Begin Phase 2 of Peptide Design Program

LIR Life Sciences has initiated Phase 2 of its peptide design program in collaboration with Neuland Laboratories. The announcement marks the continuation of their efforts to advance peptide-based therapeutic solutions, building on the progress made during the initial phase of the project.

The partnership between LIR Life Sciences and Neuland Laboratories focuses on leveraging expertise in peptide synthesis and development. The second phase aims to refine and optimize peptide designs for potential therapeutic applications. This stage will involve advanced research and development processes, including structural analysis and efficacy testing, to enhance the program’s outcomes. Both companies have expressed a commitment to advancing this initiative as part of their broader focus on innovation in life sciences.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 5, 2026

Author

GOAI